In a preclinical model of papillary renal cell carcinomas harbouring NF2 loss25, inhibition of the YAP1 partner YES1 by dasatinib or saracatinib led to repression of Hippo transcriptional targets and provided potent antitumour activity. Here, YAP1 is linked to papillary renal cell carcinoma.